SF3B1 and glioblastoma: Similarly, a higher SF3B1 expression was observed in human and mouse classical and mesenchymal GBM (subtypes with poorer survival rate) compared to proneural GBM (subtype with better survival rate) or non-tumor samples, which reinforced the prognostic value and potential oncogenic role of SF3B1 [68].